Erratum: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial (The Lancet (2014) 383(9915) (413–423) (S0140673613620371) (10.1016/S0140-6736(13)62037-1));Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): A randomised, single-blind, multicentre, non-inferiority trial

The Lancet

Volumn 383, Issue 9915, 2014, Pages 413-423

  Von Birgelen, Clemens ^a,b   Sen, Hanim ^a   Lam, Ming Kai ^a   Danse, Peter W ^c   Jessurun, Gillian A J ^d   Hautvast, Raymond W M ^e   Van Houwelingen, Gert K ^a   Schramm, Alexander R ^d   Gin, R Melvyn Tjon Joe ^c   Louwerenburg, Johannes W ^a   De Man, Frits H A F ^a   Stoel, Martin G ^a   Löwik, Marije M ^a   Linssen, Gerard C M ^f   Saïd, Salah A M ^f   Nienhuis, Mark B ^g   Verhorst, Patrick M J ^a   Basalus, Mounir W Z ^a   Doggen, Carine J M ^b   Tandjung, Kenneth ^a  

^a Thoraxcentrum Twente ^*  (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d Scheper Ziekenhuis   (Netherlands)

^e Location Alkmaar   (Netherlands)

^f Twente Hospital Group   (Netherlands)

^g Queen Beatrix Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; HEPARIN; HIRULOG; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT DEFORMATION; STENT THROMBOSIS; TARGET VESSEL RELATED MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84895072186     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60151-3     Document Type: Erratum

References (32)

1. Kastrati A, Mehilli J, Pache J., et al Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-39.
2. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254-65.
3. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention 2009; 5: 157-65.
4. Palmerini T, Biondi-Zoccai G, Della Riva D, et al Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402.
5. Stone GW, Rizvi A, Newman W., et al, for the SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-74.
6. Kedhi E, Joesoef KS, McFadden E, et al Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-09.
7. Serruys PW, Silber S, Garg S., et al Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-46.
8. von Birgelen C., Basalus MW, Tandjung K, et al A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012; 59: 1350-61.
9. Yeung AC, Leon MB, Jain A, et a.l., for the RESOLUTE US Investigators. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol 2011; 57: 1778-83.
10. Tandjung K, Basalus MW, Sen H, et al DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population. Am Heart J 2012; 163: 557-62.
11. Stone GW, Teirstein PS, Meredith I.T., et al, for the PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS Element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol 2011; 57: 1700-08.
12. Meredith IT, Whitbourn R, Scott D., et al PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention 2011; 7: 84-90.
13. Turco MA. The Integrity bare-metal stent made by continuous sinusoid technology. Expert Rev Med Devices 2011; 8: 303-06.
14. Lee SW, Chan MP, Chan KK Acute and 16-month outcomes of a new stent: the first-in-man evaluation of the Medtronic S9 (integrity) stent. Catheter Cardiovasc Interv 2011; 78: 898-908.
15. Ormiston JA, Webber B, Webster MW Stent longitudinal integrity bench insights into a clinical problem. JACC Cardiovasc Interv 2011; 4: 1310-17.
16. Abdel-Wahab M., Sulimov DS, Kassner G, Geist V., Toelg R, Richardt G. Longitudinal deformation of contemporary coronary stents: an integrated analysis of clinical experience and observations from the bench. J Interv Cardiol 2012; 25: 576-85.
17. Williams PD, Mamas MA, Morgan K.P., et al Longitudinal stent deformation: a retrospective analysis of frequency and mechanisms. EuroIntervention 2012; 8: 267-74.
18. Mamas MA, Williams PD Longitudinal stent deformation: insights on mechanisms, treatments and outcomes from the Food and Drug Administration Manufacturer and User Facility Device Experience database. EuroIntervention 2012; 8: 196-204.
19. Kim HS, Park KW, Kang S.H., et al Randomized comparison of PtCr-EES versus CoCr-ZES in all-comers receiving PCI: the HOST-ASSURE randomized trial. American College of Cardiology Scientific Sessions; San Francisco; March 9, 2013. 2667-6.
20. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-32.
21. Tandjung K, Sen H, Lam M.K., et al Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 2013; 61: 2406-16.
22. Cutlip DE, Windecker S, Mehran R., et al, for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
23. Vranckx P, Cutlip DE, Mehran R, et al Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention 2010; 5: 871-74.
24. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale: Lawrence Erlbaum, 1988.
25. Pocock SJ, Clayton TC, Altman DG Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359: 1686-89.
26. Senn S. Seven myths of randomisation in clinical trials. Stat Med 2013; 32: 1439-50.
27. Windecker S, Serruys PW, Wandel S, et al Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163-73.
28. Jensen LO, Thayssen P, Hansen H.S., et al, for the Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012; 125: 1246-55.
29. Christiansen EH, Jensen LO, Thayssen P, et a.l., for the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013; 381: 661-69.
30. Smits PC, Hofma S, Togni M., et al Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; 381: 651-60.
31. de la Torre Hernandez JM, Garcia Camarero T, Lerena P, et al. A real all-comers randomized trial comparing Xience Prime and Promus Element stents. J Invasive Cardiol 2013; 25: 182-85.
32. Kereiakes DJ, Popma JJ, Cannon L.A., et al Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. EuroIntervention 2012; 8: 187-95.